医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Solentim Expands Reach into China

2014年02月19日 AM12:25
このエントリーをはてなブックマークに追加


 

BOURNEMOUTH, United Kingdom

Solentim, the developer of imagers for single cell cloning and tools for shortening the upstream cell line development workflow, is pleased to announce that it has recently expanded its global sales reach to China by signing up two new distributors, Bio-reach Ltd., based in Beijing, and Dynamax Biotech Ltd., based in Shanghai. Furthermore, both of the new distributors have already completed their first sales of the Cell Metric to Chinese customers.

“Having established ourselves with a strong base of customer sales and installations in the US and Europe over the past three years, China now represents a tremendous growth opportunity for us with Pharma, Biotech and CRO customers involved in developing cell lines for biologics and biosimilars, and also groups working on stem cells,” commented Aaron Figg, Managing Director of Solentim.

Cell Metric provides users with market-leading clone imaging. In large part, this is due to the significantly better optics and automated cell detection capabilities the systems offer when compared to previous generation products. Thanks to these advantages, existing users have reported shaving up to three months off the development of a new cell line using Cell Metric.

Solentim will be supporting Bio-reach Ltd. on their exhibition booth at the forthcoming IBC 3rd Annual Cell Line Development & Engineering Asia Meeting to be held in Shanghai from 20th-23rd May, where customers can view the Cell Metric.

About Solentim
Commercial cell line development for biopharmaceutical production is a high value process which is intrinsically expensive and takes a significant amount of time. Solentim is dedicated to the development of innovative tools to shorten steps in the upstream cell line development workflow and facilitate cell line scale-up. The Cell Metric™ product range consists of bench-top imaging stations for QC of FACS dispensing, clone screening and id, clone growth and stability measurements.

CONTACT

Commercial Enquiries
Solentim Ltd
Dr Ian Taylor,
Sales
+44 (0) 7554 446 185
ian.taylor@solentim.com
www.solentim.com
or
Media
Enquiries

Chempetitive Group (UK office)
Dr Nicole
Liska, Science Writer
+44 (0) 1223 828 205
nliska@chempetitive.com
www.chempetitive.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent